Clinical Trial Update: Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study [Phase 2]

View source ↗

Summary

A Phase 2 exploratory trial evaluating PL-56 in patients with IgA nephropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• PL-56

Snippet

Sponsor: Calliditas Therapeutics AB | Conditions: IGA Nephropathy | Phase 2 | Status: COMPLETED